New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
New study flips the script on liver cancer

New study flips the script on liver cancer

by University of California - San DiegoUC San Diego scientists find the protein ATF4 prevents liver damage and its progression to cancer by blocking ferroptosis, an iron-dependent form of liver c
Oncology February 18,2024
New study flips the script on liver cancer

New study flips the script on liver cancer

by University of California - San DiegoUC San Diego scientists find the protein ATF4 prevents liver damage and its progression to cancer by blocking ferroptosis, an iron-dependent form of liver c
Oncology February 18,2024
Survival in Primary Hemophagocytic Lymphohistiocytosis Can Be as High as 100%

Survival in Primary Hemophagocytic Lymphohistiocytosis Can Be as High as 100%

February 2024Lara C. Pullen, PhDResults from a contemporary standard-of-care study of patients with primary hemophagocytic lymphohistiocytosis (pHLH) reveal that firstline etoposide-based therapy is m
Oncology February 18,2024
Survival in Primary Hemophagocytic Lymphohistiocytosis Can Be as High as 100%

Survival in Primary Hemophagocytic Lymphohistiocytosis Can Be as High as 100%

February 2024Lara C. Pullen, PhDResults from a contemporary standard-of-care study of patients with primary hemophagocytic lymphohistiocytosis (pHLH) reveal that firstline etoposide-based therapy is m
Oncology February 18,2024
Researchers gain structural insights into the immune modulator Siglec-15 and its interaction with T cells

Researchers gain structural insights into the immune modulator Siglec-15 and its interaction with T cells

by CIC bioGUNEa Cartoon and surface representation of two views of the crystal structure of Siglec-15 in complex with anti-Siglec-15 5G12 Fab. 5G12 is composed of a heavy chain (HC) (in orange) and a
Oncology February 18,2024
Researchers gain structural insights into the immune modulator Siglec-15 and its interaction with T cells

Researchers gain structural insights into the immune modulator Siglec-15 and its interaction with T cells

by CIC bioGUNEa Cartoon and surface representation of two views of the crystal structure of Siglec-15 in complex with anti-Siglec-15 5G12 Fab. 5G12 is composed of a heavy chain (HC) (in orange) and a
Oncology February 18,2024
Small-Volume Blood Collection Tubes Can Reduce Transfusions in Intensive Care

Small-Volume Blood Collection Tubes Can Reduce Transfusions in Intensive Care

January 2024Leah LawrenceNew data indicate that the use of tubes that automatically collect less blood in the intensive care unit (ICU) may decrease red blood cell (RBC) transfusions without affecting
Oncology February 18,2024
Small-Volume Blood Collection Tubes Can Reduce Transfusions in Intensive Care

Small-Volume Blood Collection Tubes Can Reduce Transfusions in Intensive Care

January 2024Leah LawrenceNew data indicate that the use of tubes that automatically collect less blood in the intensive care unit (ICU) may decrease red blood cell (RBC) transfusions without affecting
Oncology February 18,2024
Health Disparities Persist in Hemophilia Life Expectancy

Health Disparities Persist in Hemophilia Life Expectancy

January 2024Lara C. Pullen, PhDBetween 1999 and 2020, recorded hemophilia death (rHD) rates in the U.S. improved in males across all racial and ethnic groups.Stacey A. Fedewa, PhD, MPH,of
Oncology February 18,2024
Health Disparities Persist in Hemophilia Life Expectancy

Health Disparities Persist in Hemophilia Life Expectancy

January 2024Lara C. Pullen, PhDBetween 1999 and 2020, recorded hemophilia death (rHD) rates in the U.S. improved in males across all racial and ethnic groups.Stacey A. Fedewa, PhD, MPH,of
Oncology February 18,2024
Blood, Marrow Transplant Recipients at Increased Risk for Coronary Heart Disease

Blood, Marrow Transplant Recipients at Increased Risk for Coronary Heart Disease

November 2023Lara C. Pullen, PhDA new study reports on the long-term risk for coronary heart disease (CHD) in blood or marrow transplant (BMT) recipients and identifies individuals who are at high ris
Oncology February 18,2024
Blood, Marrow Transplant Recipients at Increased Risk for Coronary Heart Disease

Blood, Marrow Transplant Recipients at Increased Risk for Coronary Heart Disease

November 2023Lara C. Pullen, PhDA new study reports on the long-term risk for coronary heart disease (CHD) in blood or marrow transplant (BMT) recipients and identifies individuals who are at high ris
Oncology February 18,2024
Study finds TNF blockers are not associated with poor pregnancy outcomes

Study finds TNF blockers are not associated with poor pregnancy outcomes

byAmerican College of RheumatologyCredit: Pixabay/CC0 Public DomainAccording tonew researchatACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeti
Immunology & Rheumatology February 18,2024
Study finds TNF blockers are not associated with poor pregnancy outcomes

Study finds TNF blockers are not associated with poor pregnancy outcomes

byAmerican College of RheumatologyCredit: Pixabay/CC0 Public DomainAccording tonew researchatACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeti
Immunology & Rheumatology February 18,2024
Updated antiphospholipid syndrome classification criteria

Updated antiphospholipid syndrome classification criteria

by European Alliance of Associations for Rheumatology, EULARCredit: Pixabay/CC0 Public DomainAntiphospholipid syndrome (APS) is a systemic autoimmune disease associated with persistent antiphospholipi
Immunology & Rheumatology February 18,2024
Updated antiphospholipid syndrome classification criteria

Updated antiphospholipid syndrome classification criteria

by European Alliance of Associations for Rheumatology, EULARCredit: Pixabay/CC0 Public DomainAntiphospholipid syndrome (APS) is a systemic autoimmune disease associated with persistent antiphospholipi
Immunology & Rheumatology February 18,2024
Magrolimab/Azacitidine Combo Shows Efficacy for Untreated TP53-Mutant AML

Magrolimab/Azacitidine Combo Shows Efficacy for Untreated TP53-Mutant AML

December 2023Leah LawrencePatients with previously untreated acute myeloid leukemia (AML) who were not candidates for intensive chemotherapy experienced disease response when treated with a combinatio
Oncology February 18,2024
Magrolimab/Azacitidine Combo Shows Efficacy for Untreated TP53-Mutant AML

Magrolimab/Azacitidine Combo Shows Efficacy for Untreated TP53-Mutant AML

December 2023Leah LawrencePatients with previously untreated acute myeloid leukemia (AML) who were not candidates for intensive chemotherapy experienced disease response when treated with a combinatio
Oncology February 18,2024
Study finds hydroxychloroquine lowers risk of nonalcoholic fatty liver disease in rheumatoid arthritis patients

Study finds hydroxychloroquine lowers risk of nonalcoholic fatty liver disease in rheumatoid arthritis patients

byAmerican College of RheumatologyCredit: Pixabay/CC0 Public DomainNew researchatACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeting, shows that tre
Immunology & Rheumatology February 18,2024
Study finds hydroxychloroquine lowers risk of nonalcoholic fatty liver disease in rheumatoid arthritis patients

Study finds hydroxychloroquine lowers risk of nonalcoholic fatty liver disease in rheumatoid arthritis patients

byAmerican College of RheumatologyCredit: Pixabay/CC0 Public DomainNew researchatACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeting, shows that tre
Immunology & Rheumatology February 18,2024
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com